[go: up one dir, main page]

WO2018005445A1 - Compositions et méthodes pour la détection et le traitement du diabète - Google Patents

Compositions et méthodes pour la détection et le traitement du diabète Download PDF

Info

Publication number
WO2018005445A1
WO2018005445A1 PCT/US2017/039431 US2017039431W WO2018005445A1 WO 2018005445 A1 WO2018005445 A1 WO 2018005445A1 US 2017039431 W US2017039431 W US 2017039431W WO 2018005445 A1 WO2018005445 A1 WO 2018005445A1
Authority
WO
WIPO (PCT)
Prior art keywords
slc16a11
risk
protein
expression
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/039431
Other languages
English (en)
Other versions
WO2018005445A9 (fr
Inventor
Eitan HOCH
Suzanne BETH ROSENBERG JACOBS
Victor RUSU
Liping Zhao
Jose M. MERCADER BIGAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Broad Institute Inc
Harvard University
Original Assignee
Broad Institute Inc
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Institute Inc, Harvard University filed Critical Broad Institute Inc
Priority to US16/312,775 priority Critical patent/US11471462B2/en
Priority to MX2019000088A priority patent/MX2019000088A/es
Priority to EP17821057.1A priority patent/EP3474849B1/fr
Publication of WO2018005445A1 publication Critical patent/WO2018005445A1/fr
Anticipated expiration legal-status Critical
Publication of WO2018005445A9 publication Critical patent/WO2018005445A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins

Definitions

  • Type 2 diabetes afflicts -415M people worldwide, with a disproportionate impact on populations of Mexican and Latin American ancestry.
  • Type 2 or noninsulin- dependent diabetes mellitus NIDDM
  • NIDDM noninsulin- dependent diabetes mellitus
  • type 2 diabetes is a polygenic disease with complex inheritance patterns that is also influenced by environmental factors, including diet, physical activity, and age.
  • the prevalence of type 2 diabetes in Mexican and Latin American populations is roughly twice that of U.S. non-Hispanic whites. Methods of treating and preventing type 2 diabetes, particularly in Mexican and Latin American populations, are urgently required.
  • the invention features compositions and methods that are useful for increasing the level or activity of SLC16A11 in subjects having or having a propensity to develop type 2 diabetes, including, but not limited to, carriers of the SLC16A11 risk haplotype, thereby treating or preventing type 2 diabetes in those subjects.
  • the invention further provides methods of treating or preventing type 2 diabetes by increasing the activity or level of a wild- type SLC16A11 protein in a cell of the subject.
  • the invention provides a method of increasing the expression of a SLC16A11 polypeptide or a polynucleotide encoding the polypeptide in a cell, in which the method comprises contacting a cell with an agent that is a mechanistic target of rapamycin (mTOR) inhibitor.
  • mTOR mechanistic target of rapamycin
  • the method provides a method of increasing the expression of a
  • SLC16A11 polypeptide or a polynucleotide encoding the polypeptide in which the method comprises contacting an adipocyte or hepatocyte with an agent selected from the group consisting of KU-0063794, AZD-8055, NVP-BEZ235, PI- 103, WYE-354, OSI-027, and deforolimus.
  • the agent is KU-0063794 or AZD-8055. In other embodiments of the foregoing aspects, the agent increases SLC16A11 transcript levels by at least about 2-fold or 3-fold relative to the levels present in a reference cell.
  • the invention provides a method of inhibiting mTOR in a cell, in which the method comprises contacting a cell expressing mTOR with an agent selected from the group consisting of KU-0063794, AZD-8055, NVP-BEZ235, PI- 103, WYE-354, OSI- 027, and deforolimus.
  • the agent is KU-0063794 or AZD-8055.
  • the agent inhibits mTORCl and mTORC2.
  • the cell is a hepatocyte, adipocyte, thyroid cell or salivary gland cell.
  • the cell is in vitro or in vivo.
  • the invention provides a method of increasing the expression of a SLC16A11 polypeptide or a polynucleotide encoding the polypeptide in a diabetic subject, in which the method comprises administering to a subject with type 2 diabetes an effective amount of an agent selected from the group consisting of KU-0063794, AZD-8055, NVP- BEZ235, PI- 103, WYE-354, OSI-027, and deforolimus,
  • the invention provides a method of inhibiting mTOR in a diabetic subject, the method comprising administering to a subject with type 2 diabetes an agent selected from the group consisting of KU-0063794, AZD-8055, NVP-BEZ235, PI- 103, WYE-354, OSI-027, and deforolimus.
  • a method of treating or preventing type 2 diabetes in a subject comprises administering to a subject with type 2 diabetes an effective amount of an agent selected from the group consisting of KU-0063794, AZD-8055, NVP-BEZ235, PI- 103, WYE-354, OSI-027, and deforolimus.
  • the invention provides a method of increasing the expression of a SLC16A11 polypeptide or a polynucleotide encoding the polypeptide, in which the method comprises contacting a cell with an agent that is a Checkpoint Kinase (CHK) inhibitor.
  • CHK Checkpoint Kinase
  • the CHK inhibitor is AZD-7762.
  • the agent increases SLC16A11 transcript levels by at least about 3-fold, 4-fold, or 5-fold relative to the levels present in a reference cell.
  • the cell is a hepatocyte, adipocyte, thyroid cell or salivary gland cell.
  • the cell is in vitro or in vivo.
  • the subject is identified as a carrier of the SLC16A11 risk haplotype. In an embodiment of the foregoing aspects, the subject is identified as having an SLC16A11 protein comprising an amino acid alteration selected from the group consisting of VI 131, D127G, L187L, G340S, or P443T.
  • the invention provides a non-human mammal having an engineered genome comprising a loss-of-function alteration in a gene encoding a SLC16A11
  • the non-human mammal is a rodent.
  • the genome comprises a deletion that results in a truncated Slcl6al 1 protein.
  • the genome comprises Slcl6all del 19.
  • the invention provides a method of treating or preventing type 2 diabetes in a subject, in which the method comprises recombinantly expressing a wild-type SLC16A11 protein in a cell of a subject.
  • the invention provides a method of replacing a SLC16A11 gene in a subject, in which the method comprises contacting a cell in the subject with Cas9 and a SLC16A11 -specific guide RNA.
  • the invention provides a method of activating SLC16A11 transcription, in which the method comprises contacting a cell with a sgRNA plasmid comprising a SLC16A11 -specific targeting sequence, a MS2-effector plasmid, and a dCas9 plasmid, thereby activating transcription of SLC16A11.
  • the dCas9 plasmid comprises NLS-dCas9-VP64
  • the MS2-effector plasmid comprises MS2-p65-and HSF1
  • the SLC16A11 -specific targeting sequence targets sequences proximal to
  • the cell is an adipocyte, hepatocyte, myocyte, pancreatic cell, thyroid cell, salivary gland cell, and their progenitor cells, or any other cell type that expresses SLC16A11.
  • Cas9 and/or guide RNA are provided to the cell through expression from one or more expression vectors coding therefor, for example, a viral vector, such as an adeno-associated viral vector, or a non-viral vector.
  • a viral vector such as an adeno-associated viral vector, or a non-viral vector.
  • Cas9 is provided to the cell as naked plasmid DNA or chemically-modified mRNA.
  • the cell is contacted with a single-stranded oligonucleotide to effect homology directed repair.
  • the Cas9, SLC16A11 guide RNA and/or single-stranded SLC16A11 oligonucleotide are delivered directly to liver, thyroid, salivary gland, and/or muscle tissue.
  • the Cas9, SLC16A11 guide RNA and/or single-stranded SLC16A11 oligonucleotide are delivered systemically.
  • the subject is selected as a carrier of the SLC16A11 risk haplotype.
  • the cell is contacted in vitro or in vivo.
  • the invention provides an expression vector comprising a nucleic acid sequence encoding a wild-type SLC16A11 polypeptide.
  • the invention provides a host cell comprising an expression vector comprising a nucleic acid sequence encoding a wild-type SLC16A11 polypeptide.
  • the host cell is a prokaryotic or eukaryotic cell.
  • the host cell is a mammalian cell.
  • the invention provides a viral vector encoding a SLC16A11 polypeptide.
  • the invention provides an adeno-associated viral (AAV) vector encoding a SLC16A11 polypeptide, wherein the polypeptide is operably linked to a promoter positioned for expression in a mammalian cell.
  • AAV adeno-associated viral
  • the invention provides a method of treating or preventing type 2 diabetes in a subject in need thereof, in which the method comprises contacting a cell of the subject with a vector encoding a SLC16A11 polypeptide, and expressing the
  • the SLC16A11 polypeptide in the cell thereby treating or preventing type 2 diabetes in the subject.
  • the subject is identified as having the SLC16A11 risk haplotype.
  • the targeted sequence is rs77086571 or rs74577409.
  • the invention provides a method of stabilizing or enhancing expression levels of SLC16A1 1 protein in a cell, in which the method comprises contacting the cell with an agent that blocks or inhibits ubiquitination of the SLC16A11 protein at its N- terminus, thereby stabilizing or enhancing expression levels of the SLC16A1 1 protein in the cell.
  • the invention provides a method of treating, ameliorating, or preventing type 2 diabetes in a subject, in which the method comprises administering to a subject in need thereof an agent that blocks or inhibits ubiquitination of the N-terminus of the SLC16A11 polypeptide in a cell, thereby stabilizing and enhancing the expression level of the SLC16A11 polypeptide by preventing proteosomal degradation, so as to treat, ameliorate, or prevent type 2 diabetes in the subject.
  • the longevity of SLC16A11 polypeptide expression is increased in the cell.
  • the agent is a protein, polypeptide, or peptide.
  • the agent is an antibody or an antigen binding fragment thereof that specifically binds to the N-terminus of the SLC16A11 polypeptide.
  • the agent is a small molecule compound.
  • a proline residue at position 2 of the N- terminus of the SLC16A11 protein is blocked or inhibited by the agent, for example, a small molecule, or an antibody or an antigen binding fragment thereof.
  • the agent is reversibly bound to the N- terminus of the
  • the invention provides a SLC16A11 protein having bound at its N- terminus an agent that blocks or inhibits ubiquitination of the protein at the N-terminus.
  • the agent is a protein or a peptide.
  • the agent is a small molecule compound.
  • the agent blocks or masks a proline residue at position 2 of the N- terminus of the SLC16A11 protein.
  • the agent is reversibly bound to the N-terminus of the protein.
  • the invention provides a SLC16A11 protein stabilized or enhanced by the methods of the foregoing aspects.
  • compositions and articles defined by the invention were isolated or otherwise manufactured. Other features and advantages of the invention will be apparent from the detailed description herein, and from the claims.
  • Solute Carrier Family 16 member is meant a protein having 12 transmembrane (TM) helical domains with cytoplasmic N- and C- termini, a large intracellular loop between TM6 and TM7, and two highly conserved sequences; [D/E]G[G/S][W/F][G/A]W (SEQ ID NO. : 1) and YFxK[R/K][R/L]xLAx[G/A]xAxAG (SEQ ID NO.: 2) and having transport activity.
  • Exemplary SLC16 family members and their substrates are reviewed in Pochini et al. Front Chem. 2014 Aug 11;2:61. doi: 10.3389/fchem.2014.00061. eCollection 2014; also reviewed by Andrew P. Halestrap. Mol Aspects Med. 2013, Apr-Jun;34(2-3):337-49. doi: 10.1016/j .mam.2012.05.003.
  • SLC16 family members and their substrates are provided in Table 1 :

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des compositions et des méthodes qui sont utiles pour augmenter le niveau ou l'activité de SLC16A11 chez un sujet, par le traitement ou la prévention du diabète de type 2 chez le sujet.
PCT/US2017/039431 2016-06-27 2017-06-27 Compositions et méthodes pour la détection et le traitement du diabète Ceased WO2018005445A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US16/312,775 US11471462B2 (en) 2016-06-27 2017-06-27 Compositions and methods for detecting and treating diabetes
MX2019000088A MX2019000088A (es) 2016-06-27 2017-06-27 Composiciones y metodos para detectar y tratar la diabetes.
EP17821057.1A EP3474849B1 (fr) 2016-06-27 2017-06-27 Compositions et méthodes pour la détection et le traitement du diabète

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662355190P 2016-06-27 2016-06-27
US62/355,190 2016-06-27
US201762458832P 2017-02-14 2017-02-14
US62/458,832 2017-02-14

Publications (2)

Publication Number Publication Date
WO2018005445A1 true WO2018005445A1 (fr) 2018-01-04
WO2018005445A9 WO2018005445A9 (fr) 2019-02-21

Family

ID=60785512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/039431 Ceased WO2018005445A1 (fr) 2016-06-27 2017-06-27 Compositions et méthodes pour la détection et le traitement du diabète

Country Status (4)

Country Link
US (1) US11471462B2 (fr)
EP (1) EP3474849B1 (fr)
MX (1) MX2019000088A (fr)
WO (1) WO2018005445A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101920379B1 (ko) 2018-08-01 2018-11-20 엘아이지넥스원 주식회사 위성 항법 시스템 기반의 바이스태틱 합성 개구 레이더 시스템
KR101925490B1 (ko) 2018-08-01 2018-12-05 엘아이지넥스원 주식회사 위성 항법 시스템 기반의 바이스태틱 합성 개구 레이더 탐지 방법
KR20200024263A (ko) * 2017-06-30 2020-03-06 위니베르시떼 드 스트라스부르 고혈당증의 치료 및 예방을 위한 펩타이드
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
US20220333364A1 (en) * 2019-08-08 2022-10-20 Nec Platforms, Ltd. Information processing system, information processing apparatus, information processing method, and non-transitory computer-readable medium
WO2023141531A3 (fr) * 2022-01-19 2023-12-07 Orthobio Therapeutics, Inc. Édition de gène de récepteur transmembranaire
US11862306B1 (en) 2020-02-07 2024-01-02 Cvs Pharmacy, Inc. Customer health activity based system for secure communication and presentation of health information
US11926817B2 (en) 2019-08-09 2024-03-12 Nutcracker Therapeutics, Inc. Microfluidic apparatus and methods of use thereof
RU2825988C1 (ru) * 2024-04-19 2024-09-02 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ генотипирования полиморфного локуса rs1042665 (T>C) гена HSPA9 у человека методом ПЦР в режиме «реального времени» с применением аллель-специфических флуоресцентных зондов
WO2024263404A1 (fr) * 2023-06-22 2024-12-26 23Andme, Inc. Analyse et fusion de données issues d'études d'association à l'échelle du génome

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
CN112334577B (zh) 2018-04-19 2023-10-17 加利福尼亚大学董事会 用于基因编辑的组合物和方法
EP4147026A1 (fr) 2020-05-08 2023-03-15 Waters Technologies Corporation Méthodes de digestion enzymatique assistée par chauffage
US12411064B2 (en) 2020-05-08 2025-09-09 Waters Technologies Corporation Methods for heat-assisted enzyme digestion
US20240325537A1 (en) * 2021-07-19 2024-10-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cellular therapies for cancer by inhibition of monocarboxylate transporter 11
US20250084159A1 (en) * 2021-07-19 2025-03-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Mct11 antibodies to treat t cell functional exhaustion and enhance cancer immunotherapy

Citations (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656127A (en) 1983-04-22 1987-04-07 Amersham International Plc. Method of detecting mutations in DNA and RNA
FR2650840A1 (fr) 1989-08-11 1991-02-15 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
WO1992015712A1 (fr) 1991-03-05 1992-09-17 Molecular Tool, Inc. Determination d'acides nucleiques par extension de la polymerase d'oligonucleotides a l'aide de melanges terminateurs
WO1994016101A2 (fr) 1993-01-07 1994-07-21 Koester Hubert Sequençage d'adn par spectrometrie de masse
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US6306663B1 (en) * 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
US6479626B1 (en) 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US6746838B1 (en) 1997-05-23 2004-06-08 Gendaq Limited Nucleic acid binding proteins
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US20090020314A1 (en) 2007-05-21 2009-01-22 Steven Lee Dutton Direct emulsion process for making printed circuits
US7585849B2 (en) 1999-03-24 2009-09-08 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US20110145940A1 (en) 2009-12-10 2011-06-16 Voytas Daniel F Tal effector-mediated dna modification
US20120015841A1 (en) * 2009-02-02 2012-01-19 Chromocell Corporation Novel cell lines and methods
US20140068797A1 (en) 2012-05-25 2014-03-06 University Of Vienna Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140179006A1 (en) 2012-12-12 2014-06-26 Massachusetts Institute Of Technology Crispr-cas component systems, methods and compositions for sequence manipulation
US20140179770A1 (en) 2012-12-12 2014-06-26 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US20140186958A1 (en) 2012-12-12 2014-07-03 Feng Zhang Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US20140194388A1 (en) * 2011-05-26 2014-07-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
US20140242088A1 (en) * 2008-11-28 2014-08-28 Novartis Ag Hsp90 inhibitor combinations
US20140242664A1 (en) 2012-12-12 2014-08-28 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
US20140248702A1 (en) 2012-12-12 2014-09-04 The Broad Institute, Inc. CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US20140273234A1 (en) 2012-12-12 2014-09-18 The Board Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US20140295557A1 (en) 2013-03-15 2014-10-02 The General Hospital Corporation Using Truncated Guide RNAs (tru-gRNAs) to Increase Specificity for RNA-Guided Genome Editing
WO2014176281A1 (fr) * 2013-04-22 2014-10-30 Memorial Sloan Kettering Cancer Center Cristaux et modulateurs mtor
US20140335091A1 (en) 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
US20140356959A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
US20140357530A1 (en) 2012-12-12 2014-12-04 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
US20150031132A1 (en) 2013-07-26 2015-01-29 President And Fellows Of Harvard College Genome Engineering
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US20150045546A1 (en) 2012-03-20 2015-02-12 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US20150056705A1 (en) 2013-05-15 2015-02-26 Sangamo Biosciences, Inc. Methods and compositions for treatment of a genetic condition
US20150071903A1 (en) 2013-09-06 2015-03-12 President And Fellows Of Harvard College Use of cationic lipids to deliver cas9
US20150071899A1 (en) 2013-09-06 2015-03-12 President And Fellows Of Harvard College Cas9-foki fusion proteins and uses thereof
US20150159172A1 (en) 2013-12-09 2015-06-11 Sangamo Biosciences, Inc. Methods and compositions for genome engineering
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
WO2015089486A2 (fr) * 2013-12-12 2015-06-18 The Broad Institute Inc. Systèmes, procédés et compositions pour manipulation de séquences avec systèmes crispr-cas fonctionnels optimisés
US20150176027A1 (en) * 2001-12-17 2015-06-25 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
WO2015179436A1 (fr) 2014-05-19 2015-11-26 Sanford-Burnham Medical Research Institute Traitement de l'inflammation au moyen d'inhibiteurs de mekk3 ou de peptides bloquants

Patent Citations (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656127A (en) 1983-04-22 1987-04-07 Amersham International Plc. Method of detecting mutations in DNA and RNA
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
FR2650840A1 (fr) 1989-08-11 1991-02-15 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
WO1991002087A1 (fr) 1989-08-11 1991-02-21 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
WO1992015712A1 (fr) 1991-03-05 1992-09-17 Molecular Tool, Inc. Determination d'acides nucleiques par extension de la polymerase d'oligonucleotides a l'aide de melanges terminateurs
WO1994016101A2 (fr) 1993-01-07 1994-07-21 Koester Hubert Sequençage d'adn par spectrometrie de masse
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US6746838B1 (en) 1997-05-23 2004-06-08 Gendaq Limited Nucleic acid binding proteins
US6866997B1 (en) 1997-05-23 2005-03-15 Gendaq Limited Nucleic acid binding proteins
US7241574B2 (en) 1997-05-23 2007-07-10 Gendaq Ltd. Nucleic acid binding proteins
US7241573B2 (en) 1997-05-23 2007-07-10 Gendaq Ltd. Nucleic acid binding proteins
US6479626B1 (en) 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US7595376B2 (en) 1998-03-02 2009-09-29 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6903185B2 (en) 1998-03-02 2005-06-07 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6607882B1 (en) 1999-01-12 2003-08-19 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6933113B2 (en) 1999-01-12 2005-08-23 Sangamo Biosciences, Inc. Modulation of endogenous gene expression in cells
US6979539B2 (en) 1999-01-12 2005-12-27 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7220719B2 (en) 1999-01-12 2007-05-22 Sangamo Biosciences, Inc. Modulation of endogenous gene expression in cells
US6824978B1 (en) 1999-01-12 2004-11-30 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6306663B1 (en) * 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
US7585849B2 (en) 1999-03-24 2009-09-08 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20150176027A1 (en) * 2001-12-17 2015-06-25 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US20090020314A1 (en) 2007-05-21 2009-01-22 Steven Lee Dutton Direct emulsion process for making printed circuits
US20140242088A1 (en) * 2008-11-28 2014-08-28 Novartis Ag Hsp90 inhibitor combinations
US20120015841A1 (en) * 2009-02-02 2012-01-19 Chromocell Corporation Novel cell lines and methods
US20120178169A1 (en) 2009-12-10 2012-07-12 Voytas Daniel F Tal effector-mediated dna modification
US20140335618A1 (en) 2009-12-10 2014-11-13 Regents Of The University Of Minnesota Tal effector-mediated dna modification
US8440432B2 (en) 2009-12-10 2013-05-14 Regents Of The University Of Minnesota Tal effector-mediated DNA modification
US8440431B2 (en) 2009-12-10 2013-05-14 Regents Of The University Of Minnesota TAL effector-mediated DNA modification
US20130122581A1 (en) 2009-12-10 2013-05-16 Iowa State University Research Foundation, Inc. Tal effector-mediated dna modification
US8450471B2 (en) 2009-12-10 2013-05-28 Regents Of The University Of Minnesota TAL effector-mediated DNA modification
US8586363B2 (en) 2009-12-10 2013-11-19 Regents Of The University Of Minnesota TAL effector-mediated DNA modification
US8697853B2 (en) 2009-12-10 2014-04-15 Regents Of The University Of Minnesota TAL effector-mediated DNA modification
US20120178131A1 (en) 2009-12-10 2012-07-12 Voytas Daniel F Tal effector-mediated dna modification
US20120214228A1 (en) 2009-12-10 2012-08-23 Voytas Daniel F Tal effector-mediated dna modification
US20110145940A1 (en) 2009-12-10 2011-06-16 Voytas Daniel F Tal effector-mediated dna modification
US20140335592A1 (en) 2009-12-10 2014-11-13 Iowa State University Research Foundation, Inc. Tal effector-mediated dna modification
US20140194388A1 (en) * 2011-05-26 2014-07-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
US20150050699A1 (en) 2012-03-20 2015-02-19 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US20150045546A1 (en) 2012-03-20 2015-02-12 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US20140068797A1 (en) 2012-05-25 2014-03-06 University Of Vienna Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US8795965B2 (en) 2012-12-12 2014-08-05 The Broad Institute, Inc. CRISPR-Cas component systems, methods and compositions for sequence manipulation
US8993233B2 (en) 2012-12-12 2015-03-31 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US20140189896A1 (en) 2012-12-12 2014-07-03 Feng Zhang Crispr-cas component systems, methods and compositions for sequence manipulation
US20140227787A1 (en) 2012-12-12 2014-08-14 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products
US20140186958A1 (en) 2012-12-12 2014-07-03 Feng Zhang Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US20140242664A1 (en) 2012-12-12 2014-08-28 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
US20140248702A1 (en) 2012-12-12 2014-09-04 The Broad Institute, Inc. CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
US20140256046A1 (en) 2012-12-12 2014-09-11 Massachusetts Institute Of Technology Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US20140273232A1 (en) 2012-12-12 2014-09-18 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
US20150247150A1 (en) 2012-12-12 2015-09-03 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
US20150232882A1 (en) 2012-12-12 2015-08-20 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
US20140273231A1 (en) 2012-12-12 2014-09-18 The Broad Institute, Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
US20140273234A1 (en) 2012-12-12 2014-09-18 The Board Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US20150203872A1 (en) 2012-12-12 2015-07-23 The Broad Institute Inc. Crispr-cas systems and methods for altering expression of gene products
US20150184139A1 (en) 2012-12-12 2015-07-02 The Broad Institute Inc. Crispr-cas systems and methods for altering expression of gene products
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
US8871445B2 (en) 2012-12-12 2014-10-28 The Broad Institute Inc. CRISPR-Cas component systems, methods and compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US8999641B2 (en) 2012-12-12 2015-04-07 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US20140179770A1 (en) 2012-12-12 2014-06-26 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
US8889356B2 (en) 2012-12-12 2014-11-18 The Broad Institute Inc. CRISPR-Cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US8771945B1 (en) 2012-12-12 2014-07-08 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20150079681A1 (en) 2012-12-12 2015-03-19 The Broad Institute Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
US20140357530A1 (en) 2012-12-12 2014-12-04 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
US8906616B2 (en) 2012-12-12 2014-12-09 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
US8932814B2 (en) 2012-12-12 2015-01-13 The Broad Institute Inc. CRISPR-Cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US20150020223A1 (en) 2012-12-12 2015-01-15 The Broad Institute Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
US20150031134A1 (en) 2012-12-12 2015-01-29 The Broad Institute Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
US20140170753A1 (en) 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Crispr-cas systems and methods for altering expression of gene products
US20140179006A1 (en) 2012-12-12 2014-06-26 Massachusetts Institute Of Technology Crispr-cas component systems, methods and compositions for sequence manipulation
US8945839B2 (en) 2012-12-12 2015-02-03 The Broad Institute Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20160010076A1 (en) * 2013-03-15 2016-01-14 The General Hospital Corporation RNA-Guided Targeting of Genetic and Epigenomic Regulatory Proteins to Specific Genomic Loci
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US20140273233A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US20140295557A1 (en) 2013-03-15 2014-10-02 The General Hospital Corporation Using Truncated Guide RNAs (tru-gRNAs) to Increase Specificity for RNA-Guided Genome Editing
US20140295556A1 (en) 2013-03-15 2014-10-02 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to Increase Specificity for RNA-Guided Genome Editing
WO2014176281A1 (fr) * 2013-04-22 2014-10-30 Memorial Sloan Kettering Cancer Center Cristaux et modulateurs mtor
US20140335091A1 (en) 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
US20150056705A1 (en) 2013-05-15 2015-02-26 Sangamo Biosciences, Inc. Methods and compositions for treatment of a genetic condition
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
US20140356959A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
US20150031133A1 (en) 2013-07-26 2015-01-29 President And Fellows Of Harvard College Genome Engineering
US20150031132A1 (en) 2013-07-26 2015-01-29 President And Fellows Of Harvard College Genome Engineering
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US20150044191A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US20150071903A1 (en) 2013-09-06 2015-03-12 President And Fellows Of Harvard College Use of cationic lipids to deliver cas9
US20150071899A1 (en) 2013-09-06 2015-03-12 President And Fellows Of Harvard College Cas9-foki fusion proteins and uses thereof
US20150071898A1 (en) 2013-09-06 2015-03-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US20150159172A1 (en) 2013-12-09 2015-06-11 Sangamo Biosciences, Inc. Methods and compositions for genome engineering
US20150166980A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Fusions of cas9 domains and nucleic acid-editing domains
WO2015089486A2 (fr) * 2013-12-12 2015-06-18 The Broad Institute Inc. Systèmes, procédés et compositions pour manipulation de séquences avec systèmes crispr-cas fonctionnels optimisés
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
WO2015179436A1 (fr) 2014-05-19 2015-11-26 Sanford-Burnham Medical Research Institute Traitement de l'inflammation au moyen d'inhibiteurs de mekk3 ou de peptides bloquants

Non-Patent Citations (122)

* Cited by examiner, † Cited by third party
Title
"NCBI", Database accession no. NM_004958.3
"Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico", NATURE, LONDON, vol. 506, no. 7486, 25 December 2013 (2013-12-25), pages 97 - 101, ISSN: 0028-0836
"Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico", NATURE, vol. 506, no. 7486, 25 December 2013 (2013-12-25), pages 97 - 101, XP055275527 *
ANDERSON, SCIENCE, vol. 226, 1984, pages 401 - 409
ANDREW P., HALESTRAP. MOL ASPECTS MED., vol. 34, no. 2-3, pages 337 - 49
ARA KAZUO ET AL.: "BIOCHEMICAL", vol. 452, 8 August 2014, ELSEVIER, article "Genetic architecture of type 2 diabetes", pages: 213 - 220
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 2001, WILEY INTERSCIENCE
AUSUBEL, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 1987
BARANY, PROC. NATL. ACAD. SCI USA, vol. 88, 1991, pages 189
BENTONDAVIS, SCIENCE, vol. 196, 1977, pages 180
BERNSTEIN ET AL., CELL, vol. 120, 2005, pages 169 - 181
BLOOMER ET AL., JOURNAL OF VIROLOGY, vol. 71, 1997, pages 6641 - 6649
BRIGHAM ET AL., AM. J. MED. SCI., vol. 298, 1989, pages 278
CAYOUETTE ET AL., HUMAN GENE THERAPY, vol. 8, 1997, pages 423 - 430
CHRESTA ET AL., CANCER RES., vol. 70, no. 1, 1 January 2010 (2010-01-01), pages 288 - 98
CIECHANOVER, A., METHODS MOL BIOL, vol. 301, 2005, pages 255 - 270
COHEN ET AL., ADV CHROMATOGR, vol. 36, 1996, pages 127 - 162
COLIGAN, CURRENT PROTOCOLS IN IMMUNOLOGY, 1991
CORNETTA ET AL., NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, vol. 36, 1987, pages 311 - 322
COTTON ET AL., PROC. NATL ACAD SCI USA, vol. 85, 1988, pages 4397
COTTON, MUTAT RES, vol. 285, 1993, pages 125 - 144
CRONIN ET AL., HUMAN MUTATION, vol. 7, 1996, pages 244
DELANEAU, O. ET AL., NAT METHS, vol. 10, 2013, pages 5 - 6
EGLITIS ET AL., BIOTECHNIQUES, vol. 6, 1988, pages 608 - 614
ESTRADA, K. ET AL., JAMA, vol. 311, no. 22, 2014, pages 2305 - 2314
FEIGNER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 84, 1987, pages 7413
FRESHNEY, ANIMAL CELL CULTURE, 1987
FRIEDMAN, SCIENCE, vol. 244, 1989, pages 1275 - 1281
GAIT, OLIGONUCLEOTIDE SYNTHESIS, 1984
GASPARINI ET AL., MOL. CELL PROBES, vol. 6, 1992, pages 1
GEIJN, B. ET AL., NAT METHODS, vol. 12, 2015, pages 1061 - 1063
GIBBS ET AL., NUCLEIC ACIDS RES., vol. 17, 1989, pages 2437 - 2448
GOLDSTEIN, J.I. ET AL., BIOINFORMATICS, vol. 28, 2012, pages 2543 - 2545
GRIFFIN ET AL., APPL BIOCHEM BIOTECHNOL, vol. 38, 1993, pages 147 - 159
GRUNSTEINHOGNESS, PROC. NATL. ACAD. SCI., USA, vol. 72, 1975, pages 3961
HALEMARHAM, THE HARPER COLLINS DICTIONARY OF BIOLOGY, 1991
HALESTRAP ET AL., PFLUGERS ARCH., vol. 447, no. 5, February 2004 (2004-02-01), pages 619 - 28
HALESTRAP, A. ET AL., MOL. ASPECTS MED, vol. 34, 2013, pages 337 - 349
HALESTRAP, A.P. ET AL., PFLUGERS, vol. 447, 2004, pages 619 - 628
HARA ET AL.: "Genome-wide association study identifies three novel loci for type 2 diabetes", HUMAN MOLECULAR GENETICS, vol. 23, no. 1, 14 August 2013 (2013-08-14), pages 239 - 246, XP055450805 *
HAYASHI, GENET ANAL TECH APPL, vol. 9, 1992, pages 73 - 79
HEINZ, S. ET AL., MOL. CELL, vol. 38, 2010, pages 576 - 589
HSU ET AL., CARCINOGENESIS, vol. 15, 1994, pages 1657 - 1662
HUGO, S.E. ET AL., GENES DEV., vol. 26, 2012, pages 282 - 293
JINEK ET AL., SCIENCE, vol. 337, no. 6096, 17 August 2012 (2012-08-17), pages 816 - 21
JOHNSON, CHEST, vol. 107, 1995, pages 77S - 83S
KEEN ET AL., TRENDS GENET, vol. 7, 1991, pages 5
KIDO ET AL., CURRENT EYE RESEARCH, vol. 15, 1996, pages 833 - 844
KOMHER, J. S. ET AL., NUCL. ACIDS. RES., vol. 17, 1989, pages 7779 - 7784
KONERMANN ET AL., NATURE, vol. 517, 2015, pages 510 - 518
KUPPUSWAMY, M. N. ET AL., PROC. NATL. ACAD. SCI. (U.S.A, vol. 88, 1991, pages 1143 - 1147
KUROWSKIBUJNICKI, NUCL ACIDS RES, vol. 31, 2003, pages 3305 - 3307
KWOH, D. Y. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 1173 - 1177
LANDEGREN, U. ET AL., SCIENCE, vol. 241, 1988, pages 1077 - 1080
LANGMEADSALZBERG, NAT METHODS, vol. 9, 2012, pages 357 - 359
LE GAL LA SALLE ET AL., SCIENCE, vol. 259, 1993, pages 988 - 990
LIAO ET AL., MOL CELL BIOL, vol. 31, 2014, pages 2591 - 2604
LIZARDI, P. M. ET AL., BIO/TECHNOLOGY, vol. 6, 1988, pages 1197
MALI ET AL., SCIENCE, vol. 339, no. 6121, 15 February 2013 (2013-02-15), pages 823 - 6
MAURANO ET AL., SCIENCE, vol. 337, 2012, pages 1190 - 1195
MAXIMGILBERT, PROC. NATL ACAD SCI USA, vol. 74, 1977, pages 560
MIKKELSEN ET AL., NATURE, vol. 448, 2007, pages 553 - 560
MILLER ET AL., BIOTECHNOLOGY, vol. 7, 1989, pages 980 - 990
MILLER, HUMAN GENE THERAPY, 1990, pages 15 - 14
MILLERCALOS, GENE TRANSFER VECTORS FOR MAMMALIAN CELLS, 1987
MIYOSHI ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 94, 1997, pages 10319
MOEN, BLOOD CELLS, vol. 17, 1991, pages 407 - 416
MULLIS, PCR: THE POLYMERASE CHAIN REACTION, 1994
MUOIO, D.M.NEWGARD, C.B., NAT REV MOL CELL BIOL, vol. 9, 2008, pages 193 - 205
MYERS ET AL., NATURE, vol. 313, 1985, pages 495
MYERS ET AL., SCIENCE, vol. 230, 1985, pages 1242
NALDINI ET AL., SCIENCE, vol. 272, 1996, pages 263 - 267
NEWMAN ET AL.: "Ketone bodies as signaling metabolites", TRENDS IN ENDOCRINOLOGY & METABOLISM, vol. 25, no. 1, 18 October 2013 (2013-10-18), pages 42 - 52, XP055450799 *
NG, M.C. ET AL., PLOS GENET, vol. 10, 2014, pages e1004517
NG, M.C. ET AL., PLOS GENETICS, vol. 10, 2014, pages el004517
NICKERSON, D. A. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8923 - 1878
NYREN, P. ET AL., ANAL. BIOCHEM., vol. 208, 1993, pages 171 - 175
ONO ET AL., NEUROSCIENCE LETTERS, vol. 17, 1990, pages 259
ORITA ET AL., PROC NATL. ACAD. SCI USA, vol. 86, 1989, pages 2766
POCHINI ET AL., FRONT CHEM., vol. 2, 11 August 2014 (2014-08-11), pages 61
PREZANT, T. R. ET AL., HUM. MUTAT., vol. 1, 1992, pages 159 - 164
RAPPSILBER ET AL., NAT PROTOC., vol. 2, no. 8, 2007, pages 1896 - 1906
RINK, T.J. ET AL., J CELL BIOL, vol. 95, 1982, pages 189 - 196
ROEST, HUM. MOL. GENET., vol. 2, 1993, pages 1719 - 21
ROSENBERG ET AL., N. ENGL. J. MED, vol. 323, 1990, pages 370
RYCHLEWSKI, L. ET AL., PROTEIN SCI, vol. 9, 2000, pages 232 - 241
SAIKI ET AL., NATURE, vol. 324, 1986, pages 163
SAIKI ET AL., PROC. NATL ACAD. SCI USA, vol. 86, 1989, pages 6230
SALEEBA ET AL., METHODS ENZYMOL., vol. 217, 1992, pages 286 - 295
SALI, A.BLUNDELL, T.L., J MOL BIOL, vol. 234, 1993, pages 779 - 815
SAMBROOK: "Molecular Cloning: A Laboratory Manual", 1989
SAN MARTIN, A. ET AL., PLOS ONE, vol. 9, 2014, pages e85780
SANGER ET AL., PROC. NAT. ACAD. SCI USA, vol. 74, 1977, pages 5463
SANJ ANA, N.E. ET AL., NAT METHODS, vol. 11, 2014, pages 783 - 784
SCHEUNER ET AL.: "The Unfolded Protein Response: A Pathway That Links Insulin Demand with beta-Ce)) Failure and Diabetes", ENDOCRINE REVIEWS, vol. 29, no. 3, 1 May 2008 (2008-05-01), pages 317 - 333, XP055450807 *
See also references of EP3474849A4
SHALEM, O. ET AL., SCIENCE, vol. 343, 2014, pages 84 - 87
SHARP, THE LANCET, vol. 337, 1991, pages 1277 - 1278
SIEVERS, F. ET AL., MOL SYST BIOL, vol. 7, 2011, pages 539
SIGMA T2D CONSORTIUM ET AL., NATURE, vol. 506, 2014, pages 97 - 101
SIGMA, NATURE, vol. 506, no. 7486, 6 February 2014 (2014-02-06), pages 97 - 101
SOKOLOV, B. P., NUCL. ACIDS RES., vol. 18, 1990, pages 3671
STAUBINGER ET AL., METHODS IN ENZYMOLOGY, vol. 101, 1983, pages 512
SUHRE, K. ET AL., NATURE, vol. 477, 2011, pages 54 - 60
SYVANEN, A.-C. ET AL., AMER. J. HUM. GENET., vol. 52, 1993, pages 46 - 59
SYVANEN, A.-C. ET AL., GENOMICS, vol. 8, 1990, pages 684 - 692
TOBE ET AL., NUCLEIC ACIDS RES, vol. 24, 1996, pages 3728
TOLSTOSHEV ET AL., CURRENT OPINION IN BIOTECHNOLOGY, vol. 1, 1990, pages 55 - 61
TOOLEY ET AL.: "New roles for old modifications: Emerging roles of N-terminal post-translational modifications in development and disease", PROTEIN SCIENCE, vol. 23, no. 12, 26 September 2014 (2014-09-26), pages 1641 - 1649, XP055450803 *
TRAURIG, M. ET AL., DIABETES, vol. 65, 2016, pages 510 - 519
UDESHI, N.D. ET AL., MOL. CELL PROTEOMICS, vol. 11, 2012, pages 148 - 159
UGOZZOLI, L. ET AL., GATA, vol. 9, 1992, pages 107 - 112
VAN DER LUIJT, GENOMICS, vol. 20, 1994, pages 1 - 4
VON GROTTHUSS, M. ET AL., PROTEINS, vol. 53, 2003, pages 418 - 423
WAHL, G. M.S. L. BERGER, METHODS ENZYMOL., vol. 152, 1987, pages 507
WAKEFIELD, J., J HUM GENET, vol. 81, 2007, pages 208 - 227
WEIR: "Handbook of Experimental Immunology", 1996, article "Methods in Enzymology"
WILLER, C.J. ET AL., BIOINFORMATICS, vol. 26, 2010, pages 2190 - 2191
WOLFF ET AL., SCIENCE, vol. 247, 1990, pages 1465
WU ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, 1988, pages 14621
WU ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, 1989, pages 16985
ZHANG ET AL., J BIOMOL SCREEN., vol. 4, no. 2, 1999, pages 67 - 73

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200024263A (ko) * 2017-06-30 2020-03-06 위니베르시떼 드 스트라스부르 고혈당증의 치료 및 예방을 위한 펩타이드
KR102696075B1 (ko) 2017-06-30 2024-08-19 위니베르시떼 드 스트라스부르 고혈당증의 치료 및 예방을 위한 펩타이드
KR101920379B1 (ko) 2018-08-01 2018-11-20 엘아이지넥스원 주식회사 위성 항법 시스템 기반의 바이스태틱 합성 개구 레이더 시스템
KR101925490B1 (ko) 2018-08-01 2018-12-05 엘아이지넥스원 주식회사 위성 항법 시스템 기반의 바이스태틱 합성 개구 레이더 탐지 방법
US11920335B2 (en) * 2019-08-08 2024-03-05 Nec Platforms, Ltd. Information processing system, information processing apparatus, information processing method, and non-transitory computer-readable medium
US20220333364A1 (en) * 2019-08-08 2022-10-20 Nec Platforms, Ltd. Information processing system, information processing apparatus, information processing method, and non-transitory computer-readable medium
US11926817B2 (en) 2019-08-09 2024-03-12 Nutcracker Therapeutics, Inc. Microfluidic apparatus and methods of use thereof
US12448618B2 (en) 2019-08-09 2025-10-21 Nutcracker Therapeutics, Inc. Microfluidic apparatus and methods of use thereof
US12492394B2 (en) 2019-08-09 2025-12-09 Nutcracker Therapeutics, Inc. Microfluidic apparatus and methods of use thereof
US11862306B1 (en) 2020-02-07 2024-01-02 Cvs Pharmacy, Inc. Customer health activity based system for secure communication and presentation of health information
US12068062B2 (en) 2020-02-07 2024-08-20 Cvs Pharmacy, Inc. Customer health activity based system for secure communication and presentation of health information
US11903916B2 (en) 2020-04-10 2024-02-20 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
WO2023141531A3 (fr) * 2022-01-19 2023-12-07 Orthobio Therapeutics, Inc. Édition de gène de récepteur transmembranaire
WO2024263404A1 (fr) * 2023-06-22 2024-12-26 23Andme, Inc. Analyse et fusion de données issues d'études d'association à l'échelle du génome
RU2825988C1 (ru) * 2024-04-19 2024-09-02 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ генотипирования полиморфного локуса rs1042665 (T>C) гена HSPA9 у человека методом ПЦР в режиме «реального времени» с применением аллель-специфических флуоресцентных зондов

Also Published As

Publication number Publication date
EP3474849A1 (fr) 2019-05-01
EP3474849B1 (fr) 2025-05-21
EP3474849A4 (fr) 2020-07-29
US20190350938A1 (en) 2019-11-21
MX2019000088A (es) 2019-08-29
US11471462B2 (en) 2022-10-18
WO2018005445A9 (fr) 2019-02-21

Similar Documents

Publication Publication Date Title
EP3474849B1 (fr) Compositions et méthodes pour la détection et le traitement du diabète
Vardarajan et al. Rare coding mutations identified by sequencing of A lzheimer disease genome‐wide association studies loci
Marçano et al. TBX22 mutations are a frequent cause of cleft palate
Fingerlin et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
Borck et al. BRF1 mutations alter RNA polymerase III–dependent transcription and cause neurodevelopmental anomalies
Wang et al. A missense mutation in HK1 leads to autosomal dominant retinitis pigmentosa
Tort et al. Exome sequencing identifies a new mutation in SERAC1 in a patient with 3-methylglutaconic aciduria
Cui et al. Multiple polymorphisms within the PLCE1 are associated with esophageal cancer via promoting the gene expression in a Chinese Kazakh population
JP2016047058A (ja) 疾患危険因子を同定する方法
Aldhorae et al. Nonsyndromic cleft lip with or without cleft palate in arab populations: Genetic analysis of 15 risk loci in a novel case–control sample recruited in Yemen
Perrin et al. Chromatin accessibility and gene expression during adipocyte differentiation identify context-dependent effects at cardiometabolic GWAS loci
Jung et al. Mutations causing Lopes-Maciel-Rodan syndrome are huntingtin hypomorphs
Kumar et al. Homozygous mutation of STXBP5L explains an autosomal recessive infantile-onset neurodegenerative disorder
Ivarsdottir et al. Gene-based burden tests of rare germline variants identify six cancer susceptibility genes
WO2013169956A2 (fr) Compositions et procédés pour la modulation de l'activité d'un support mitochondrial du pyruvate
Cortes et al. Resequencing and fine-mapping of the chromosome 12q13-14 locus associated with multiple sclerosis refines the number of implicated genes
Wills et al. Chromosomal abnormalities in hepatic cysts point to novel polycystic liver disease genes
Zhang et al. Association of polymorphisms in PATE1 gene with idiopathic asthenozoospermia in Sichuan, China
Guaragna et al. Two distinct WT1 mutations identified in patients and relatives with isolated nephrotic proteinuria
Wang et al. The mtDNA replication-related genes TFAM and POLG are associated with leprosy in Han Chinese from Southwest China
US12383566B2 (en) Inhibition of SLC transporter activity or expression to attenuate anthracycline-induced cardiotoxicity
Li et al. The rs11191580 variant of the NT5C2 gene is associated with schizophrenia and symptom severity in a South Chinese Han population: evidence from GWAS
WO2018170289A1 (fr) Procédés de détermination du vieillissement différentiel et de modificateurs génétiques de gènes corrélés à un génotype d'intérêt
WO2012044987A2 (fr) Modificateurs génétiques de la mucoviscidose
WO2015168252A1 (fr) Nombre de copies d'adn mitochondrial en tant que prédicteur de fragilité osseuse, de maladie cardiovasculaire, de diabète et de mortalité toutes causes confondues

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17821057

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017821057

Country of ref document: EP

Effective date: 20190128

WWG Wipo information: grant in national office

Ref document number: 2017821057

Country of ref document: EP